Net product sales increased 28% over third quarter 2006 to $177 million
SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2007. The Company reported total revenue of $190.0 million for the third quarter, including net product sales of $177.4 million. Net loss for the quarter ended September 30, 2007 was $39.8 million, or $0.30 per share. At September 30, 2007, the Company held cash, cash equivalents and short-term investments of approximately $1.1 billion.
"BYETTA and SYMLIN, our first-in-class diabetes medicines, have been on the market for nearly 30 months and continued to show growth in physician adoption, prescriptions and reported revenue in the third quarter," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "Additionally we continued to advance our pipeline drug candidates and remain on track to report key clinical data later this quarter from our once-weekly exenatide long-acting release program and our integrated neurohormone obesity program."
Quarter ended September 30, 2007
Net product sales of $177.4 million for the third quarter include $161.1 million for BYETTA(R) (exenatide) injection and $16.3 million for SYMLIN(R) (pramlintide acetate) injection. This compares to net product sales of $138.8 million, consisting of $126.4 million for BYETTA and $12.4 million for SYMLIN for the same period in 2006.
Revenues under collaborative agreements were $12.6 million for the
quarter ended September 30, 2007, compared to $8.2 million for the same
period in 2006. The increase reflects higher cost-sharing payments from
Lilly to equalize develo
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved